Check-Cap (MBAI) Competitors

$1.76 -0.10 (-5.11%)

As of 03:37 PM Eastern

MBAI vs. SRTS, LUNG, NSPR, ECOR, and COCH

Should you buy Check-Cap stock or one of its competitors? MarketBeat compares Check-Cap with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Check-Cap include Sensus Healthcare (SRTS), Pulmonx (LUNG), InspireMD (NSPR), electroCore (ECOR), and Envoy Medical (COCH). These companies are all part of the "medical equipment" industry.

How does Check-Cap compare to Sensus Healthcare?

Check-Cap (NASDAQ:MBAI) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Check-Cap has higher earnings, but lower revenue than Sensus Healthcare. Sensus Healthcare is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Sensus Healthcare	$27.48M	1.91	-$7.72M	-$0.47	N/A

Check-Cap has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Sensus Healthcare has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Sensus Healthcare has a consensus price target of $6.88, suggesting a potential upside of 115.45%. Given Sensus Healthcare's stronger consensus rating and higher probable upside, analysts clearly believe Sensus Healthcare is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 10.2% of Sensus Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Check-Cap has a net margin of 0.00% compared to Sensus Healthcare's net margin of -34.50%. Check-Cap's return on equity of 0.00% beat Sensus Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Sensus Healthcare	-34.50%	-15.79%	-14.02%

In the previous week, Sensus Healthcare had 2 more articles in the media than Check-Cap. MarketBeat recorded 3 mentions for Sensus Healthcare and 1 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.00 beat Sensus Healthcare's score of -0.08 indicating that Check-Cap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensus Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sensus Healthcare beats Check-Cap on 9 of the 15 factors compared between the two stocks.

How does Check-Cap compare to Pulmonx?

Pulmonx (NASDAQ:LUNG) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Pulmonx currently has a consensus target price of $5.58, suggesting a potential upside of 261.38%. Given Pulmonx's stronger consensus rating and higher probable upside, equities analysts plainly believe Pulmonx is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Check-Cap has a net margin of 0.00% compared to Pulmonx's net margin of -60.09%. Check-Cap's return on equity of 0.00% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-60.09%	-92.94%	-39.80%
Check-Cap	N/A	N/A	N/A

In the previous week, Check-Cap had 1 more articles in the media than Pulmonx. MarketBeat recorded 1 mentions for Check-Cap and 0 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.00 equaled Check-Cap'saverage media sentiment score.

Company	Overall Sentiment
Pulmonx	Neutral
Check-Cap	Neutral

Pulmonx has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Check-Cap has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

Check-Cap has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$90.50M	0.72	-$54M	-$1.30	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 6.8% of Pulmonx shares are held by insiders. Comparatively, 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Pulmonx and Check-Cap tied by winning 7 of the 14 factors compared between the two stocks.

How does Check-Cap compare to InspireMD?

InspireMD (NYSE:NSPR) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Check-Cap has lower revenue, but higher earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$10.85M	4.36	-$19.92M	-$0.73	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

44.8% of InspireMD shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 34.1% of InspireMD shares are held by company insiders. Comparatively, 0.5% of Check-Cap shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

InspireMD has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Check-Cap has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

In the previous week, InspireMD had 14 more articles in the media than Check-Cap. MarketBeat recorded 15 mentions for InspireMD and 1 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.00 beat InspireMD's score of -0.69 indicating that Check-Cap is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InspireMD	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Check-Cap has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. Check-Cap's return on equity of 0.00% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
Check-Cap	N/A	N/A	N/A

InspireMD presently has a consensus price target of $4.50, suggesting a potential upside of 345.54%. Given InspireMD's stronger consensus rating and higher probable upside, research analysts plainly believe InspireMD is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

InspireMD beats Check-Cap on 9 of the 15 factors compared between the two stocks.

How does Check-Cap compare to electroCore?

Check-Cap (NASDAQ:MBAI) and electroCore (NASDAQ:ECOR) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Check-Cap has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, electroCore has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

In the previous week, electroCore had 1 more articles in the media than Check-Cap. MarketBeat recorded 2 mentions for electroCore and 1 mentions for Check-Cap. electroCore's average media sentiment score of 0.56 beat Check-Cap's score of 0.00 indicating that electroCore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
electroCore	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Check-Cap has a net margin of 0.00% compared to electroCore's net margin of -44.08%. Check-Cap's return on equity of 0.00% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
electroCore	-44.08%	-1,956.38%	-83.30%

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 0.5% of Check-Cap shares are held by company insiders. Comparatively, 13.8% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

electroCore has a consensus target price of $18.00, suggesting a potential upside of 176.50%. Given electroCore's stronger consensus rating and higher probable upside, analysts clearly believe electroCore is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Check-Cap has higher earnings, but lower revenue than electroCore. electroCore is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
electroCore	$32.03M	1.69	-$13.97M	-$1.77	N/A

Summary

electroCore beats Check-Cap on 10 of the 15 factors compared between the two stocks.

How does Check-Cap compare to Envoy Medical?

Check-Cap (NASDAQ:MBAI) and Envoy Medical (NASDAQ:COCH) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Check-Cap has higher earnings, but lower revenue than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Envoy Medical	$240K	226.48	-$23.76M	-$1.01	N/A

Check-Cap has a net margin of 0.00% compared to Envoy Medical's net margin of -9,875.64%.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Envoy Medical	-9,875.64%	N/A	-177.92%

Envoy Medical has a consensus target price of $6.00, suggesting a potential upside of 748.66%. Given Envoy Medical's stronger consensus rating and higher possible upside, analysts clearly believe Envoy Medical is more favorable than Check-Cap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 8.6% of Envoy Medical shares are held by institutional investors. 0.5% of Check-Cap shares are held by insiders. Comparatively, 7.1% of Envoy Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Check-Cap has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Envoy Medical has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

In the previous week, Check-Cap and Check-Cap both had 1 articles in the media. Envoy Medical's average media sentiment score of 0.30 beat Check-Cap's score of 0.00 indicating that Envoy Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Envoy Medical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Envoy Medical beats Check-Cap on 9 of the 13 factors compared between the two stocks.

Get Check-Cap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBAI vs. The Competition

Export

Metric	Check-Cap	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$12.87M	$3.24B	$4.24B	$12.33B
Dividend Yield	N/A	N/A	6.21%	5.33%
P/E Ratio	-0.64	2.85	22.04	25.75
Price / Sales	N/A	32.29	122.48	98.92
Price / Cash	3.22	4.40	53.85	56.16
Price / Book	3.76	3.17	34.77	7.03
Net Income	$4.14M	-$76.79M	$112.32M	$335.04M
7 Day Performance	-0.28%	1.50%	1.77%	2.72%
1 Month Performance	11.01%	-5.52%	2.83%	1.53%
1 Year Performance	N/A	97.45%	16.14%	35.73%

Check-Cap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBAI Check-Cap	0.2499 of 5 stars	$1.77 -5.1%	N/A	N/A	$12.87M	N/A	N/A	80	Positive News
SRTS Sensus Healthcare	3.5234 of 5 stars	$3.40 +0.9%	$6.88 +102.2%	-31.4%	$55.80M	$27.48M	N/A	40
LUNG Pulmonx	1.9321 of 5 stars	$1.32 +1.9%	$5.38 +309.0%	-51.0%	$55.55M	$90.50M	N/A	250
NSPR InspireMD	3.7923 of 5 stars	$1.16 -3.8%	$4.50 +289.6%	-53.6%	$54.10M	$10.85M	N/A	50	Trending News
ECOR electroCore	2.7033 of 5 stars	$6.26 -6.5%	$18.00 +187.4%	+21.7%	$51.98M	$32.03M	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBAI) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Check-Cap (MBAI) Competitors

MBAI vs. SRTS, LUNG, NSPR, ECOR, and COCH

How does Check-Cap compare to Sensus Healthcare?

Summary

How does Check-Cap compare to Pulmonx?

Summary

How does Check-Cap compare to InspireMD?

Summary

How does Check-Cap compare to electroCore?

Summary

How does Check-Cap compare to Envoy Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBAI vs. The Competition

Check-Cap Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Check-Cap (MBAI) Competitors

MBAI vs. SRTS, LUNG, NSPR, ECOR, and COCH

How does Check-Cap compare to Sensus Healthcare?

Which has stronger earnings & valuation, MBAI or SRTS?

Which has more risk & volatility, MBAI or SRTS?

Do analysts recommend MBAI or SRTS?

Do institutionals & insiders hold more shares of MBAI or SRTS?

Is MBAI or SRTS more profitable?

Does the media refer more to MBAI or SRTS?

Summary

How does Check-Cap compare to Pulmonx?

Do analysts rate LUNG or MBAI?

Is LUNG or MBAI more profitable?

Does the media favor LUNG or MBAI?

Which has more risk and volatility, LUNG or MBAI?

Which has better earnings and valuation, LUNG or MBAI?

Do institutionals & insiders believe in LUNG or MBAI?

Summary

How does Check-Cap compare to InspireMD?

Which has preferable valuation and earnings, NSPR or MBAI?

Do insiders & institutionals believe in NSPR or MBAI?

Which has more risk & volatility, NSPR or MBAI?

Does the media favor NSPR or MBAI?

Is NSPR or MBAI more profitable?

Do analysts prefer NSPR or MBAI?

Summary

How does Check-Cap compare to electroCore?

Which has more risk & volatility, MBAI or ECOR?

Does the media refer more to MBAI or ECOR?

Is MBAI or ECOR more profitable?

Do institutionals & insiders hold more shares of MBAI or ECOR?

Do analysts prefer MBAI or ECOR?

Which has better earnings & valuation, MBAI or ECOR?

Summary

How does Check-Cap compare to Envoy Medical?

Which has preferable valuation & earnings, MBAI or COCH?

Is MBAI or COCH more profitable?

Do analysts prefer MBAI or COCH?

Do institutionals and insiders believe in MBAI or COCH?

Which has more volatility & risk, MBAI or COCH?

Does the media refer more to MBAI or COCH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBAI vs. The Competition

Check-Cap Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools